RELAÇÃO DOS ELEMENTOS BIOQUÍMICOS E FARMACOLÓGICOS COM O DESENVOLVIMENTO DE COMPLICAÇÕES CARDÍACAS EM PORTADORES DE COVID-19: REVISÃO DE LITERATURA
DOI:
10.46551/ruc.v23n1a01Keywords:
COVID-19; SARS-CoV-2; Cardiovascular diseasesAbstract
Justification and Objectives: The choice for this theme is important because it is a recently discovered disease that is generating a great impact worldwide, and is therefore of high scientific relevance. The objective was to describe the biochemical and pharmacological elements and their relationship with the development or worsening of cardiac changes in patients with COVID-19. Content: This is an integrative literature review with search for articles in three databases: Medical Literature Analysis and Retrieval System Online (MEDLINE), Latin American Literature in Health Sciences (LILACS) and SUS collections consulted through the Library Virtual Health (BVS Brasil), from June 1 to 18, 2020. 11 articles comprised this review. A flowchart was made showing the following topics: data collection; selection of records; analysis of the selection by title or abstract;
eligibility assessment; studies included for the construction of the synoptic framework. Conclusion: There is a relationship between COVID-19 and the development and / or worsening of cardiovascular changes, this relationship can be mediated by the action of the angiotensin-converting enzyme (ACE 2) and elevated levels of D-dimers. Patients with cardiovascular, hypertensive and diabetics have higher expression of ACE 2, which contributed to increase the chance of becoming infected by the virus. It was not possible to confirm whether antihypertensive drugs are related to the development of COVID-19.
Downloads
References
TAO, C, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJag., China. 12(1):3-17, mar.,2020. doi:https://doi.org/10.1136/bmj.m1091. Access in: 16 jun. 2020.
CHEN, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Mag. Lancet Published Online 395: 507–13., January, 2020. doi:https://doi.org/10.1016/S0140- 6736(20)30211-7 . Access en: 16 jun.2020.
ZAID, A, et al. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications in cardiovascular complications related to SARS-CoV-2.American Physiological Society, Jerusalém, Israel. 318(5):1080-83, mar., 2020. doi:https://doi.org/10.1152/ajpheart.00215.2020. Access in: 16 ago. 2020.
HUANG, Chaolin et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Published Online 395: 497–506., Jan., 2020. doi:https://doi.org/10.1016/S0140-6736(20)30183-5. Access in: 16 ago.2020.
DAVID, S. Hui et al., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. Rev. Elservier., 91 (2020) 264–266., Jan. 2020. doi: https://doi.org/10.1016/j.ijid.2020.01.009. Access in: 16 ago.2020.
NA, Z et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. Mag. N Engl J Med ; 382(8): 727-733., february, 2020. doi:10.1056/nejmoa2001017.
MINISTÉRIO DA SAÚDE (BR). Diretrizes para Diagnóstico e Tratamento da Covid19 Versão 1 Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde – SCTIE. Brasília-DF abril 2020. p 398. Access en: 16 jun.2020..
MORENO, M, et al., Cardiovascular repercussions of infection by the new SARSCoV-2 coronavirus (COVID-19). Mag.CorSalud, [S.l.], v. 12, n. 1, p. 3-17, abr. 2020. doi:article/view/588/1113. Access en: 16 jun.2020.
MINISTÉRIO DA SAÚDE (BR). Protocolo de Manejo Clínico do Coronavírus (Covid-19) na Atenção Primária à Saúde: Diretrizes para Diagnóstico e Tratamento da Covid-19 Versão 9. Secretaria de Atenção Primária à Saúde (SAPS) Brasília-DF maio2020. p 41. Access en: 16 jun.2020.
CHATE, RC et al., Presentation of pulmonary infection on CT in COVID-19: initial experience in Brazil. J. bras. pneumol. [Internet]; 2020;46(2):e20200121. Apr., 2020. doi:https://doi.org/10.36416/1806-3756/e20200121. Access in: 16 ago.2020.
. LANA, Raquel Martins et al., The novel coronavirus (SARS-CoV-2) emergency and the role of timely and effective national health surveillance. Cad. Saúde Pública [Internet]; 36(3):e00019620. Epub., Mar, 2020. doi: https://doi.org/10.1590/0102-311x00019620. Access in: 16 ago.2020.
MEHRA, MR, et al., Cardiovascular Disease, Drug Therapy, and Mortality in Covid19. Mag. N Engl J Med., 382(25): e102, Jun2020. doi:/doi/full/10.1056/NEJMoa2007621. Access en: 16 jun.2020.
WANG, D, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan. JAMA., China. 323(11):1061– 1069. Feb. 2020. doi:10.1001/jama.2020.1585. Access in: 16 ago. 2020.
WORLD, Health Organization. New coronavirus (2019-nCoV): status report- 15. Feb, 2020. Available in: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200204-sitrep-15-ncov.pdf. Access in: 16 ago. 2020.
SUN, P, et al. Understanding of COVID-19 based on current evidence. Mag. J MedVirol. 92:548–551, 2020. doi:https://doi.org/10.1002/jmv.25722. Access en: 16 jun.2020.
HAN, Y, et al. Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic. J Cardiovasc Magn Reson 22., 26 (2020)., Apr., 2020.doi:https://doi.org/10.1186/s12968-020-00628-w. Access in: 16 ago.2020.
HAN, Y, et al., Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic. Mag. Circulation; 141(20): e810-e816, may.2020 May.
doi:10.1161/CIRCULATIONAHA.120.047011. Access en: 16 jun.2020.
ELKIND, MSV; Harrington RA; Benjamin IJ. The Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020;141(15):e743-e745. doi: 10.1161 / CIRCULATIONAHA.120.046749. Access in: 16 ago. 2020.
ASKIN, Lutfu; Tanrıverdi Okan; Askin Husna Sengul. The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases. Arq. Bras. Cardiol. [Internet]. 2020 Mai 2020. 114(5):817-822. doi: http://dx.doi.org/10.36660/abc.20200273. Access in: 16 ago.2020.
CHENG, P, et al.,Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Curr Cardiol Rep. 22, 34 (2020). doi:/10.1007/s11886-020-01293-2. Access en: 16 jun.2020.
FREDERIC, S, et al. Use of drugs with a potential cardiac effect in the definition of SARS-CoV-2 infection. Elsevier Masson France., França. 113 (5): 293–296, mai., 2020. doi: 10.1016 / j.acvd.2020.04.003. Access in: 16 ago. 2020.
GHEBLAWI, M, et al., Enzima Conversora de Angiotensina 2: Receptor SARS-CoV-2 e Regulador do Sistema Renina-Angiotensina; Comemorando o 20º aniversário da descoberta do ACE2. Circ Res., 126: 1456–1474., apr., 2020.
doi:/10.1161/CIRCRESAHA.120.317015. Access en: 12 jun.2020.
ZHOU F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–62.,march, 2020. doi:/10.1016/S0140-6736(20)30566-3. Access en: 16 jun 2020.
AKHMEROV, A; Marbán E. COVID-19 and the Heart. Circ Res., 126(10): 1443- 1455, mai., 2020. doi:/10.1161/CIRCRESAHA.120.317055. Access en: 12 jun.2020.
ZHENG, YY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. China. 17, 259–260 (2020). doi:/10.1038/s41569-020-0360-5. Access in: 14 jun. 2020.
R, Ferrari; G. Di Pasquale; C. Rapezzi. Commentary: What is the relationship between Covid-19 and cardiovascular disease?. Commentary., 310(2020) P167-168., July 2020. doi: https://doi.org/10.1016/j.ijcard.2020.03.074. Access in: 16 ago.2020.
MUSHTAQ, H, et al., Structural Variations in Human ACE2 may Influence its Binding with SARS-CoV-2 Spike Protein. J Med Virol., Pakistan.apr., 2020. doi:https://doi.org/10.1002/jmv.25832 .Access en: 12 jun.2020.
GIUSEPPE, Mancia, et al., Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; 382: 2431-2440., Jun, 2020. doi:10.1056/NEJMoa2006923. Access in: 16 ago.2020.
TOUYZ RM, Li H, Delles C. ACE2 the Janus-faced protein – from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci (Lond)., United Kingdom. 134 (7): 747–750apr., 2020. doi:10.1042/CS20200363. Access in: 12 jun. 2020.
IACCARINO, G, et al., Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.High Blood Press Cardiovasc Prev., 27, 105–108 (2020). doi:10.1007/s40292-020-00380-3. Access en: 12 jun.2020.
Published
Versions
- 2021-05-30 (2)
- 2021-05-30 (1)
